Document is current
Any future updates will be listed below
-
Authors
La Rosa, Alonso https://orcid.org/0000-0002-9814-2642
Mittauer, Kathryn E.
Rzepczynski, Amy E.
Chuong, Michael D. https://orcid.org/0000-0001-8328-7518
Bassiri-Gharb, Nema
McAllister, Nicole C.
Hall, Matthew D. https://orcid.org/0000-0001-8768-3577
Press, Robert H. https://orcid.org/0000-0002-3297-3945
Gutierrez, Alonso N.
Tolakanahalli, Ranjini
Mehta, Minesh P. https://orcid.org/0000-0002-4812-5713
Kotecha, Rupesh https://orcid.org/0000-0001-6927-0402
- License Information
-
More Information
Article History
Received: 4 March 2025
Accepted: 21 April 2025
First Online: 29 April 2025
Declarations
:
: ALR: GT Medical Technologies Travel and expenses. KEM: reports ownership interest in a company that provides consulting services on image guided radiation therapy technology (MR Guidance, LLC.). She received travel reimbursement/consulting fees/speaking fees/grants from ViewRay Inc. MDC: Honoraria from ViewRay Inc. and institutional research funding from ViewRay Inc., Novocure Inc., Stratpharma Inc. ANG: Honoraria for Elekta AB,Zap Surgical Inc, IBA AB, CQ Medical. Consulting fees for Elekta AB. MPM: Consulting Fees from AIQ, Mevion, Novocure, Telix, Kazia Therapeutics, Zap, Xoft; Stock in Chimerix. RK: Honoraria from Accuray Inc., Elekta AB, ViewRay Inc., Novocure Inc., Elsevier Inc., Brainlab, Kazia Therapeutics, Castle Biosciences, and institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, AstraZeneca, Exelixis, ViewRay Inc., Brainlab, Cantex Pharmaceuticals, and Kazia Therapeutics. All remaining authors declare no conflicts of interest.
